Endometrial Cancer:

Sirexatamab (DKN-01) in endometrial cancer

Patients with endometrial cancer have a high frequency of mutations in a protein known as beta-catenin. These beta-catenin mutations are often driver mutations leading to high expression of DKK1, rapid disease progression, and poor outcomes. Sirexatamab (DKN-01) has demonstrated single agent activity in endometrial cancer patients, including a patient with a complete response. The activity of sirexatamab (DKN-01) in endometrial cancer was strongest in patients whose tumors were expressing high levels of DKK1.

• DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma
• Safety and Efficacy of a DKK1 Inhibitor (DKN-01) as Monotherapy or in Combination with Paclitaxel in Patients with Wnt Activated Recurrent Gynecologic Malignancies.
• Patients with recurrent epithelial endometrial cancers (EEC) demonstrated greater clinical benefit in biomarker-selected populations when treated with DKN-01 monotherapy.
• Response to anti-DKK1 Therapy in Uterine Carcinosarcoma: A Case Report